- Conditions
- Achondroplasia
- Interventions
- Not listed
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Oakland, California • Wilmington, Delaware + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 10,525
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ductus Arteriosus, Patent
- Interventions
- Transcatheter PDA Closure
- Device
- Lead sponsor
- Le Bonheur Children's Hospital
- Other
- Eligibility
- 3 Days to 1 Year
- Enrollment
- 5,000 participants
- Timeline
- 2020 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Pectus Excavatum
- Interventions
- Hydromorphone, Morphine
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Tourette's Disorder, Insomnia
- Interventions
- Forehead Temperature-Regulating Therapy
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hemophilia A
- Interventions
- Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 11
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Lexington, Kentucky + 8 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Romosozumab, Bisphosphonate
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
- Conditions
- Cleft Palate
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- Up to 24 Months
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Erythropoietic Protoporphyria (EPP), X-Linked Porphyria (XLP)
- Interventions
- Not listed
- Lead sponsor
- Portal Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Wake Forest, North Carolina + 2 more
- Conditions
- Wilson's Disease
- Interventions
- VTX-801
- Genetic
- Lead sponsor
- Vivet Therapeutics SAS
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 6
- States / cities
- Sacramento, California • New Haven, Connecticut • Orlando, Florida + 3 more
- Conditions
- Gout
- Interventions
- Not listed
- Lead sponsor
- jasvinder singh
- Federal
- Eligibility
- 18 Years to 110 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Skin Carcinoma
- Interventions
- tazarotene, placebo
- Drug · Other
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 3
- States / cities
- Oakland, California • New York, New York
- Conditions
- Cystic Fibrosis, Liver Disease
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Gout
- Interventions
- SEL-037 (pegsiticase)
- Biological
- Lead sponsor
- Selecta Biosciences, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Duncansville, Pennsylvania • Dallas, Texas
- Conditions
- Colorectal Carcinoma, Lynch Syndrome
- Interventions
- Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration
- Biological · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Genetic Conditions, Genetic Disorders
- Interventions
- RNA sequencing
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cardiovascular Disease, Acute Rejection of Cardiac Transplant, Cardiac Transplant Rejection, Heart Transplant Failure and Rejection
- Interventions
- Blood Draw of up to 10 ml
- Diagnostic Test
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Not listed
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Romosozumab, Calcium, Vitamin D
- Drug · Dietary Supplement
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin
- Conditions
- Atopic Dermatitis
- Interventions
- Tralokinumab
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 78 more
- Conditions
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Interventions
- Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
- Biological
- Lead sponsor
- AC Immune SA
- Industry
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
- Conditions
- Neurofibromatosis Type 1, Plexiform Neurofibromas
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Miami, Florida + 7 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
- Interventions
- ATV-1601, Placebo
- Drug
- Lead sponsor
- Atavistik Bio, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Augusta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
- Interventions
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
- Drug · Radiation · Device + 1 more
- Lead sponsor
- Alice Bertaina
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
- Interventions
- Erythropoietin, Sham Comparator
- Drug · Other
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 24 Hours to 96 Days
- Enrollment
- 318 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2000
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more